- Home
- VEL vs PSNL Comparison
VEL vs PSNL Comparison
Compare VEL & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | PSNL |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.4M | 746.8M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VEL | PSNL |
|---|---|---|
| Price | $18.64 | $8.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.75 | $11.00 |
| AVG Volume (30 Days) | 114.1K | ★ 1.4M |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.26 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $229,360,000.00 | $69,103,000.00 |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $27.31 | $20.33 |
| P/E Ratio | $7.66 | ★ N/A |
| Revenue Growth | ★ 116.81 | N/A |
| 52 Week Low | $16.12 | $2.83 |
| 52 Week High | $21.40 | $11.40 |
Technical Indicators
Market Signals| Indicator | VEL | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 45.13 |
| Support Level | $18.01 | $7.72 |
| Resistance Level | $21.40 | $9.74 |
| Average True Range (ATR) | 0.61 | 0.53 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 17.70 | 18.56 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.